Congratulations to Drs. Victoria Hoskin and Abdi Ghaffari, and MD/PhD candidate Brian Laight and co-authors on their recent paper in Cancer Research Communications entitled “Targeting the Ezrin Adaptor Protein Sensitizes Metastatic Breast Cancer Cells to Chemotherapy and Reducing Neoadjuvant Therapy-induced Metastasis”. This study is the latest in the ongoing Ezrin story, which was initiated here at Queen’s University by Dr. Bruce Elliott as a basic science research project. Bruce subsequently convinced clinical colleagues Drs. Sandip SenGupta, Yolanda Madarnas and Sonal Varma to explore Ezrin as a prognostic biomarker in breast cancer. This was the origin of the Southeastern Ontario Breast Cancer (SEOBC) cohort tissue microarray; a resource that is now being led by Dr. Chris Nicol. Although Dr. Hoskin has recently moved on to a new career opportunity developing cancer vaccines, her Ezrin research continues as an inhibitor development project led by Dr. Ghaffari (supported by the Ontario Institute of Health Research) and continuing mechanistic studies driven by Brian Laight, Yan Gao and Changnian Shi (support by the Canadian Cancer Society).